KCL-286   Click here for help

GtoPdb Ligand ID: 12792

Synonyms: BHBA-001 | BHBA001 | C-286 | C286 | compound 10 [PMID: 30792038] | KCL286
Compound class: Synthetic organic
Comment: This compound is reported as an orally bioavailable retinoic acid receptor beta (RARβ) agonist, that activates the RARβ2 subtype [2] that is involved in neurite outgrowth/axonal regeneration [1,4]. It is predicted to stimulate nerve regrowth as a mechanism to treat spinal cord injuries.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 80.48
Molecular weight 334.33
XLogP 2.23
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1=CC=C(C)C2=C1C=C(C3=NC(=NO3)C4=CC=C(C=C4)C(=O)O)O2
Isomeric SMILES CC1=CC=C(C)C2=C1OC(=C2)C3=NC(=NO3)C4=CC=C(C=C4)C(O)=O
InChI InChI=1S/C19H14N2O4/c1-10-3-4-11(2)16-14(10)9-15(24-16)18-20-17(21-25-18)12-5-7-13(8-6-12)19(22)23/h3-9H,1-2H3,(H,22,23)
InChI Key AVCXUODHLRZJJP-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
As KCL-286 the compound was progressed to clinical evaluation in study ISRCTN12424734 with study results published in August 2023 [3]. Tolerability, target engagement and receptor activation were confirmed in healthy study volunteers.